Race and Prognosis of Brain Tumor Patients Entering Multicenter Clinical Trials

1996 ◽  
Vol 19 (2) ◽  
pp. 114-120 ◽  
Author(s):  
Joseph R. Simpson ◽  
Charles B. Scott ◽  
Marvin Rotman ◽  
Walter J. Curran ◽  
Louis S. Constine ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Brain Tumor ◽  
Tumor Patients ◽  
Multicenter Clinical Trials

scholarly journals Barriers to accrual and enrollment in brain tumor trials

2019 ◽  
Author(s):  
Eudocia Q Lee ◽  
Ugonma N Chukwueke ◽  
Shawn L Hervey-Jumper ◽  
John F de Groot ◽  
Jose Pablo Leone ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Clinical Trials ◽  
Brain Tumor ◽  
Response Assessment ◽  
Adult Brain ◽  
Cooperative Groups ◽  
Tumor Patients ◽  
Cancer Society ◽  
Clinical Trial Accrual ◽  
Patient Advocacy Groups

Abstract Many factors contribute to the poor survival of malignant brain tumor patients, some of which are not easily remedied. However, one contributor to the lack of progress that may be modifiable is poor clinical trial accrual. Surveys of brain tumor patients and neuro-oncology providers suggest that clinicians do a poor job of discussing clinical trials with patients and referring patients for clinical trials. Yet, data from the Cancer Action Network of the American Cancer Society suggest that most eligible oncology patients asked to enroll on a clinical trial will agree to do so. To this end, the Society for Neuro-Oncology (SNO) in collaboration with the Response Assessment in Neuro-Oncology (RANO) Working Group, patient advocacy groups, clinical trial cooperative groups, including the Adult Brain Tumor Consortium (ABTC), and other partners are working together with the intent to double clinical trial accrual over the next 5 years. Here we describe the factors contributing to poor clinical trial accrual in neuro-oncology and offer possible solutions.

scholarly journals Application of CLN-IgG/Pritumumab against COVID-19 Infectivity from the Aspect of Tumor-PIVIEMT Scheme

2021 ◽  
Vol 5 (1) ◽  
Author(s):  
Hugwil AV
Keyword(s):  
Monoclonal Antibody ◽  
Wound Healing ◽  
Clinical Trials ◽  
Stem Cell ◽  
Brain Tumor ◽  
Human Monoclonal Antibody ◽  
Tactile Sensor ◽  
Virus Infectivity ◽  
Virus Propagation ◽  
Tumor Patients

The touch/tactile sensor PIEZO1/2 and vimentin network is the critical conduit for COVID-19 virus infectivity. Coordination of PIEZO1/2 and vimentin network in regard to EMT/MET which is actual accordance of PIVEMT is critical for stem cell sustenance and wound healing of the injured cells and tissues in inflammation. On the contrary PIVIEMT discordance, deteriorated PIEZO1/2-Vimentin network, provokes pathogenic symptoms such as severe autoimmunopathies. From this aspect imminent treatment is necessary to recuperate the patients from onset of pathogens and/or neoplasms by use of chaperonic antibody that is able to restore/resile the pathogenic PIVIEMT as seen in the clinical trials against brain tumor patients with repetitive administration of the natural human monoclonal antibody CLN-IgG/Pritumumab. Targeting the virus conduit with the chaperonic antibody is highly expected for not only shutting down the virus infectivity but also augmentation of the antibody-directed vaccination against virus propagation.

Clinical Trials Update

2009 ◽  
Vol 8 (2) ◽  
pp. 99-99
Keyword(s):  
Clinical Trials ◽  
Pulmonary Hypertension ◽  
Preliminary Results ◽  
Multicenter Clinical Trials

We would like to introduce you to a new section in Advances in Pulmonary Hypertension in which we highlight results from ongoing and recent clinical trials. The preliminary results of several multicenter clinical trials have recently been presented. In this issue, we will focus on the results of Freedom-C, which was presented in November of 2008, as well as the Walk-PHaSST study, which was stopped early in July 2009.

scholarly journals Genetic variants and cognitive functions in patients with brain tumors

2019 ◽  
Vol 21 (10) ◽  
pp. 1297-1309 ◽  
Author(s):  
Denise D Correa ◽  
Jaya Satagopan ◽  
Axel Martin ◽  
Erica Braun ◽  
Maria Kryza-Lacombe ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Cell Cycle ◽  
Dna Repair ◽  
Brain Tumor ◽  
Brain Tumors ◽  
Cell Cycle Regulation ◽  
Cognitive Outcome ◽  
Cholesterol Transport ◽  
Tumor Patients ◽  
Cycle Regulation

AbstractBackgroundPatients with brain tumors treated with radiotherapy (RT) and chemotherapy (CT) often experience cognitive dysfunction. We reported that single nucleotide polymorphisms (SNPs) in the APOE, COMT, and BDNF genes may influence cognition in brain tumor patients. In this study, we assessed whether genes associated with late-onset Alzheimer’s disease (LOAD), inflammation, cholesterol transport, dopamine and myelin regulation, and DNA repair may influence cognitive outcome in this population.MethodsOne hundred and fifty brain tumor patients treated with RT ± CT or CT alone completed a neurocognitive assessment and provided a blood sample for genotyping. We genotyped genes/SNPs in these pathways: (i) LOAD risk/inflammation/cholesterol transport, (ii) dopamine regulation, (iii) myelin regulation, (iv) DNA repair, (v) blood–brain barrier disruption, (vi) cell cycle regulation, and (vii) response to oxidative stress. White matter (WM) abnormalities were rated on brain MRIs.ResultsMultivariable linear regression analysis with Bayesian shrinkage estimation of SNP effects, adjusting for relevant demographic, disease, and treatment variables, indicated strong associations (posterior association summary [PAS] ≥ 0.95) among tests of attention, executive functions, and memory and 33 SNPs in genes involved in: LOAD/inflammation/cholesterol transport (eg, PDE7A, IL-6), dopamine regulation (eg, DRD1, COMT), myelin repair (eg, TCF4), DNA repair (eg, RAD51), cell cycle regulation (eg, SESN1), and response to oxidative stress (eg, GSTP1). The SNPs were not significantly associated with WM abnormalities.ConclusionThis novel study suggests that polymorphisms in genes involved in aging and inflammation, dopamine, myelin and cell cycle regulation, and DNA repair and response to oxidative stress may be associated with cognitive outcome in patients with brain tumors.

Sign in / Sign up

Export Citation Format

Share Document